Beating the Odds: Combating Premature Heart Disease through CKM Science | Dr Enas A Enas

"Lipoprotein(a) is a genetic variant of LDL cholesterol that explains the extreme prematurity and severity of heart disease in Indians, which standard risk factors cannot fully account for," said Dr. Enas A. Enas in a conversation with Dr. P.C. Manoria at the World Congress Cardio Kidney Metabolic (WC CKM) Medicine 2026.

Top 5 Key Takeaways:

1 Lp(a) Prevalence: Present in 25% of Indians; drives premature, severe heart attacks unexplained by standard risk factors.
2 Unexplained Severity: Standard factors (smoking, BP, diabetes) fail to account for the extreme prematurity and diffuse disease seen in Indian patients.
3 Stringent Targets: High-risk patients must aggressively lower LDL to 40–60 mg/dL, starting as early as age 20 or 30.
4 Selective Aspirin Use: Aspirin reduces heart attack risk by 40–50% specifically in those with high Lp(a).
5 siRNA Revolution: New RNA therapies (Pelacarsen, Lepodisiran) can lower Lp(a) by up to 98%; availability expected this decade.

Dr. Enas A. Enas is a global pioneer in the study of heart disease among South Asians. As the founder of the CADI Research foundation, he led the landmark CADI study involving 2,000 Indian physicians, which first identified the fourfold higher rate of CAD in this ethnic group. His decades of research have established Lipoprotein(a) as a primary determinant of premature cardiovascular mortality in Indians.

Dr. Professor P.C. Manoria is the Executive President for the World Congress Cardio Kidney Metabolic (WC CKM) Medicine. He is a distinguished cardiologist and a leading figure in South Asia for integrating cardio-renal-metabolic care to address the epidemic of non-communicable diseases.

Video Timestamps

00:00 Introduction: The Rampant Epidemic of CAD in India
01:07 Identifying the Phenomenon: Heart Attacks in the 20s and 30s
02:05 The CADI Study: Why Standard Risk Factors Aren't Enough
02:59 Lipoprotein(a): The Genetic Variant Driving Severity
04:08 Ethnic Risk Enhancers: Indian Origin and Lp(a)
04:58 Emerging Therapeutics: Pelacarsen and Phase 3 Trials
05:50 The Role of Aspirin in Patients with High Lp(a)
06:36 The Future: siRNA Molecules (Pelacarsen, Lepodisiran, Olpasiran)
07:22 Life Essential Eight: Lifestyle Management for High-Risk Patients
08:45 Evolution of Syndromes: From Framingham to Cardio-Metabolic-Kidney (CKM)
10:21 Closing Remarks and the Importance of CKM Education

#WCCKM2026 #DrEnasAEnas #DrPCManoria #Lp(a) #LipoproteinA #HeartDiseaseIndia #Cardiology #CAD #GeneticRisk #siRNA #TheRightDoctors #TRD

Our recognitions:

Google Launchpad (USD200,000 in platform credit over two tranches), Berlin Bootcamp, Startup Networkz Singapore (Start-Up of Substance), and NASSCOM Showcase Start-Up.

Subscribe for more videos: https://bit.ly/2X2gQmF
Our Social Media Links:
Facebook - https://goo.gl/YO1oel
Twitter - https://goo.gl/J1gtvw
LinkedIn - https://bit.ly/368sfGb
Web - https://bit.ly/36qI3ma

#TheRightDoctors #TRD

© TheRightDoctors Knowledge Network. All rights reserved.